It’s no surprise that an underperforming site can cause significant delays in meeting important accrual…
As of May 2020 ClinicalTrials.gov lists 16,150 oncology trials registered as Recruiting, Not yet Recruiting Studies, and the chart below illustrates the distribution of these oncology trials by Phase (P1&2 or P3) and by geographic location (U.S. only or global).
The larger patient pool necessary for Phase 3 trials often requires a global scope, in addition to laying the path for eventual drug approval requests in more than one region. Conducting a Phase 3 oncology trial across multiple regions also allows for access to a more demographically diverse patient population and mitigate different types of enrollment barriers.
For smaller biotech companies the stakes are high for any Phase 3 trial. With limited resources and pipelines, successful execution of a global Phase 3 trial is critical as outcomes may determine the future of the compound and possibly the ultimate survival of the company itself.
Oncology is both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend in relation to the phases of clinical trial research likely to continue into 2024 is the expectation that the market is to be dominated by Phase 3 trials.
At the same time year-over-year the attributes Sponsors seek from their clinical trial outsourcing partners remains the same. Quality and reliability are the number one and number two priorities.
A Region of Interest for Phase 3 Global Studies
Coinciding with overall global clinical trial market growth to 2024 is an expected 3-fold treatable population increase resulting from a growing, aging population worldwide. Close in geographic and cultural proximity to the U.S., Canada’s average annual number of cancer cases is projected to be 79% higher in 2028–2032 than it was in 2003–2007. While participation by Canadians in oncology clinical trials is 14%. Nearly triple the 5% participation rate in the U.S.
In addition, Canadian cancer patients are funneled through select oncology health centers across the country and will typically receive treatment at the same center throughout the evolution of their disease (1st, 2nd line, 3rd line, etc). A factor that greatly aids in identification of possible oncology trial participants.
Canada currently ranks 5th among countries (excluding the U.S.) that contribute the greatest number of clinical trial participants globally. While the number of physicians per population has increased in Canada over the past decade, and is expected to continue to increase for the next several years.
Results Achieved with the Right Partner
Based on the metrics achieved by Canadian oncology CRO, Scimega, biotechs developing cutting edge oncology therapies with this partner are quoted as being very impressed with where Canada stands in comparison to other regions, including the U.S., when they work together in the region.
Scimega guarantees Sponsors the quickest site start-up and the highest patient recruitment rate, without sacrificing premium quality data. Site identification and qualification of the right Canadian sites is completed within just a few weeks thanks to Scimega’s extensive network of Canadian Investigators. These Canadian sites are then activated 50% faster than the industry average, and frequently emerge among top enrollers in sponsors’ global oncology studies.
What Your Specialized Oncology CRO Can Do for You – Real World Evidence
Mobilizing an expert Canadian team significantly enhances study start-up and overall performance. The following real-world case featured here highlights how an unwavering strategic focus of a specialized oncology CRO delivers on its commitment to the Sponsor’s program.
The case in point is a sophisticated global Phase 3 immuno-oncology study in mRCC sponsored by a U.S. oncology biotech that had been ongoing for 14 months in other global regions with slow enrollment due to logistical complexities associated with fresh tumor sample collection & access to a leukapheresis lab.
The client was told by their Global CRO that expansion to Canada was not a good option.
Happily, an encounter with Scimega convinced the sponsor’s clinical operations team otherwise, and proof of the wisdom of their decision was quickly delivered when Canada started-up 5 sites in just over 9 weeks.
Further evidence of this right choice came with Canadian sites’ recruitment performance outstripping that of European sites’ performance by 2.5:1 patients/site.
Given its stable, experienced teamwork and ability to identify, advise on, and implement enrollment strategies within the complex field of oncology clinical research this specialized oncology CRO was instrumental in developing the solution to get this important global trial back on track.
Your Specialized Oncology CRO – Scimega Consistently Goes Above-and-Beyond
With 22 years unparalleled Canadian oncology experience Scimega Research has an optimal operations design critical to its ability to consistently go above-and-beyond for every one of your studies.
Scimega is a Canadian niche oncology CRO that serves small to medium size biotech companies in clinical development of cutting-edge oncology therapies. We consistently deliver our services with a strategic focus on Sponsor program success with clinical trial start-up times 50% faster than the North American average, premium quality data, and trial sites that are often among top enrollers in our Sponsors’ global oncology studies.
Contributed by: Julie Martin, Director, Clinical Operations
American Association of Medical Colleges Canadian Cancer Statistics 2019
Applied Clinical Trials: Planning for Success in Late Phase Global Oncology Trials, 2015
Canadian Institute for Health Information
Changing Paradigms in Clinical Trials: Market Landscape – 2019-2050 report
Eurostat https://ec.europa.eu Lifescienceleader.com
Memorial Sloan Kettering Cancer Center